Tadeu Ambros, MD
Medical Oncology · Cape Coral, FLNPI 1245551134
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,791 of the $19,876 with a category attached, or 79.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $6,001, more than ten times the $11 reported in 2019.
Across 785 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Partner Therapeutics, Inc.$3K
- Incyte Corporation$2K
- Merck$1K
- Pfizer$1K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$971
- plus $10K from 54 others
Across 3 payments — averaging $210.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$632
What the payments were for
- Consulting fees$3,84019%
- Speaking & faculty fees$2001%
- Food & beverage$15,79179%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bizengri$2,400
- MONJUVI$1,440
- TAGRISSO$250
- LYNPARZA$125
- Da Vinci Surgical System$124
How this compares
$19,876 in reported general payments places this provider in the 70th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 68 | $1,099,375 |
| IbrancePalbociclib | 27 | $409,751 |
| PomalystPomalidomide | 17 | $380,347 |
| KisqaliRibociclib Succinate | 20 | $292,338 |
| BrukinsaZanubrutinib | 15 | $187,981 |
| NubeqaDarolutamide | 14 | $167,919 |
| AlecensaAlectinib Hcl | 12 | $162,202 |
| PegasysPeginterferon Alfa-2a | 14 | $57,425 |
| EliquisApixaban | 69 | $53,247 |
| XareltoRivaroxaban | 23 | $20,844 |
| Anastrozole | 183 | $3,351 |
| Imatinib Mesylate | 30 | $2,916 |
| Hydroxyurea | 62 | $2,041 |
| Tamoxifen Citrate | 58 | $1,773 |
| Oxycodone Hcl | 91 | $1,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $903 | $1,099,37568 claims |
| PfizerIbrance, Eliquis | $1,323 | $462,99996 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $971 | $380,34717 claims |
| NovartisKisqali | $820 | $292,33820 claims |
| Beigene USA, Inc.Brukinsa | $120 | $187,98115 claims |
| BayerNubeqa | $366 | $167,91914 claims |
| Genentech USA, Inc.Alecensa | $216 | $162,20212 claims |
| Johnson & JohnsonXarelto | $1,023 | $20,84423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Cape Coral
- Faithlore GardnerCape Coral$74K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.